(Press-News.org) Anyone involved in macromolecular crystallography will know that for many years scientists have had to rely on a multi-stage process utilizing protein, usually expressed in engineered cells, which is then extracted and purified before crystallization in vitro and finally prepared for analysis.
As a counter to this time-consuming and substantial scientific effort, there are a number of examples of protein crystallization events occurring in vivo, with next to no human input. In a case presented in a recent paper an insect virus exploits the phenomenon as part of its life cycle. Not surprisingly an issue with intracellular protein crystals is that they are typically very small, limited by the size of the cell. However, microfocus beamlines at synchrotron light sources prove here to be capable and refined in the analysis of micron-scale in vivo samples.
A group of scientists from the Diamond Light Source and the University of Oxford, UK [Axford et al. (2014), Acta Cryst. D70, 1435-1441; doi:10.1107/S1399004714004714] has been able to study crystals inside the cells directly using X-ray analysis without complex attempts to extract and prepare samples. It would not be out of place to assume that the presence of cellular material might compromise the experiment. However, the researchers' results show that the exact opposite may actually be true; the cell maintains the crystals in an environment amenable to the collection of data.
It will be interesting to see if an improved understanding of protein crystallization in vivo can bring more targets within reach of such analysis. Certainly continued technical developments, including increased photon flux and reduced beam size, will improve the signal-to-noise ratio. Together with more efficient data processing, this means that we will be able to do more with less and exploit novel microcrystal targets of increasing complexity for in vivo structural studies.
INFORMATION: END
Doing more with less; in cellulo structure determinations
2014-06-02
ELSE PRESS RELEASES FROM THIS DATE:
BRCA2 gene now connected to lung cancer, doubling a smoker's risk
2014-06-02
New research confirms a vulnerability to lung cancer can be inherited and implicates the BRCA2 gene as harboring one of the involved genetic mutations. An international consortium of scientists including investigators at the Institute for Cancer Research in London, the International Agency for Research on Cancer in Lyon, the National Cancer Institute in Bethesda, Harvard, and Dartmouth used integrated results from the 1000 Genomes Project with genetics studies of lung cancer to complete the investigation published on June 1, 2014 in Nature Genetics.
The study scanned ...
Transforming hydrogen into liquid fuel using atmospheric CO2
2014-06-02
Hydrogen is often touted as the fuel of the future. But because this gas is highly explosive, it must be stored and transported under pressure in specialized and expensive containers. Hydrogen therefore has issues in terms of safety, logistics, and profitability that could significantly limit its wider use. However, a solution might lie in research by EPFL scientists, who have developed a simple system based on two chemical reactions. The first reaction transforms hydrogen into formic acid, a liquid that is easy to store and less flammable than gasoline, while the second ...
Small businesses less likely to offer health promotion programs
2014-06-02
Employees at small businesses are less likely to have access to worksite wellness programs, according to a research review in the May Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
But smaller companies that can overcome the barriers and implement wellness programs can realize achieve meaningful improvements in employee health, report Kira McCoy, BA, of Hampshire College, Amherst, Mass., and colleagues. They write, "Preventative health initiatives and disease management ...
CPAP rapidly improves blood pressure and arterial tone in adults with sleep apnea
2014-06-02
DARIEN, IL – A new study suggests that continuous positive airway pressure (CPAP) therapy rapidly improves blood pressure and arterial tone in adults with obstructive sleep apnea (OSA).
Results show that there was a significant reduction in systolic and diastolic blood pressures among sleep apnea patients who were compliant with CPAP therapy for three months. Successful treatment of sleep apnea also was associated with decreased vascular tone and arterial stiffness. Following one week of treatment withdrawal, these improvements disappeared and reverted to baseline values.
"We ...
Studies reveal new strategies to improve quality of life
2014-06-02
CHICAGO – Key studies released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) identify new strategies for easing the short- and long-term effects of cancer therapy and improving the quality of life of patients with cancer, as well as their caregivers.
"We've made incredible strides in cancer treatment, and more cancer survivors are alive today than ever before. But oncology isn't just about helping people live longer – we need to ensure that patients have the best quality of life possible at every stage of their cancer journey, from ...
Studies reveal potential new targeted therapies for common, hard-to-treat cancers
2014-06-02
CHICAGO – Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). Findings from the mid- and late-stage trials suggest new ways to slow disease progression and improve survival for patients who experience relapses or resistance to available treatments.
"Cancer relapses and treatment resistance have always been among the most daunting challenges in cancer care," said ...
Clinical trial shows drug combination may be highly effective in recurrent ovarian cancer
2014-06-02
VIDEO:
Dr. Joyce Liu talks about her ovarian cancer research at ASCO 2014.
Click here for more information.
CHICAGO –– Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today. This is the first ovarian cancer study to use a combination of drugs that could be taken orally. The drugs were tested in a phase I combination study followed ...
Drug combination extends survival by more than a year in metastatic prostate cancer
2014-06-02
VIDEO:
Dr. Christopher Sweeney talks about his new study showing a drug combination extends survival by more than a year in metastatic prostate cancer.
Click here for more information.
CHICAGO – Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute ...
Prostate cancer drug delivers benefits before chemotherapy
2014-06-02
PORTLAND, Ore. – A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University (OHSU).
A comprehensive analysis of the study's results ― published in June 1 online edition of the New England Journal of Medicine and to be presented at the American Society of Clinical Oncology (ASCO) annual ...
Researchers to provide update on Phase II trial of vaccine for malignant brain tumors
2014-06-02
LOS ANGELES (STRICTLY EMBARGOED UNTIL 7:30 A.M. EDT on JUNE 1, 2014 - ASCO Abstract No. 2005) – A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.
They will present their findings in an oral presentation June 1 at the annual meeting ...